Epigenetic Therapy Market TO Grow At A CAGR Of 14.8% Forecas...| MENAFN.COM

Tuesday, 09 August 2022 03:09 GMT

Epigenetic Therapy Market TO Grow At A CAGR Of 14.8% Forecast From 2021 To 2030


(MENAFN- EIN Presswire)

Epigenetics Market by Product

The global epigenetics market was valued at $1.0 billion in 2020, and is projected to reach $4.1 billion by 2030, growing at a CAGR of 14.8% from 2021 to 2030.

PORTLAND, OREGON, UNITED STATES, August 4, 2022 /EINPresswire.com / -- How do epigenetics work?

Epigenetics is the study of how your behaviors and environment can cause changes that affect the way your genes work. Unlike genetic changes, epigenetic changes are reversible and do not change your DNA sequence, but they can change how your body reads a DNA sequence.

Technological advancements, rise in prevalence of cancer, and increase in genome mapping programs and number of R&D activities drive the growth of the global epigenetics market . However, standardization concerns regarding epigenetics-based diagnostics and lack of skilled professionals hamper the market growth. On the contrary, untapped potential in developing countries is expected to create lucrative opportunities for the market players in the future.

For Right Perspective, Download Sample PDF at: (Flash Sale Tell 20th August 2022):

The global epigenetics market was valued at $1.0 billion in 2020, and is projected to reach $4.1 billion by 2030, growing at a CAGR of 14.8% from 2021 to 2030.

Drivers, restraints, and opportunities-

High-end technological advancements associated with epigenetics, rise in incidences of cancer, surge in genome mapping programs, and growing number of R&D activities drive the global epigenetics market. On the other hand, standardization concerns over epigenetics-based diagnostics and dearth of skilled professionals impede the growth to some extent. However, several growth opportunities in the emerging economies have created an array of lucrative prospects for the key players in the industry.

The growth of the global epigenetics market is attributed to increase in oncology cases, surge of other chronic diseases and its rising application for non-oncology applications. Moreover, increase in R & D for epigenetics is expected to further drive the market growth during the forecast period.

Covid-19 scenario:

Since the Covid-19 outbreak, researchers have been working to find a vaccine against Covid-19 virus. In addition, the use of targeted antiviral therapies such as rapamycin, remdesivir, ribavirin, and other epigenetic drugs have been demonstrated to inhibit the infection.

Researchers have been trying to understand how epigenetics could prevent viral proliferation, so that vaccines could be developed to specifically target the replicating mechanism of virus.

During the pandemic, the number of epigenetic research activities and awareness regarding epigenetic drugs have been increased.

Ask to Our Industry Expert: (Flash Sale Tell 20th August 2022):

The oncology segment to dominate by 2030-

On the basis of application, the oncology segment contributed to the lion's share in 2020, holding more than two-thirds of the global epigenetics market. This is attributed to the large number of cancer cases across the globe. However, the non-oncology segment is projected to manifest the fastest CAGR of 15.3% from 2021 to 2030. Rise in chronic diseases especially cardiac and metabolic disorders drives the segment growth.

North America held the major share in 2020-

By region, the market across North America dominated in 2020, garnering nearly of the global epigenetics market, owing to rapid adoption of advanced technologies and presence of key players across North America. Simultaneously, Asia-Pacific is expected to cite the fastest CAGR of 16.3% throughout the forecast period, due to rise in R & D activities for epigenetics services and increase in healthcare investment in the region.

Key players in the industry-

Abcam Plc.
PerkinElmer, Inc.
Zymo Research
QIAGEN N.V.
Merck Millipore
Agilent Technologies, Inc.
Illumina Inc.
Active Motif, Inc.
Hologic Inc.
Thermo Fisher Scientific Inc.

We also Offers Regional and Country Reports-

Japan Early Toxicity Testing Market
South Korea Early Toxicity Testing Market
Singapore Early Toxicity Testing Market
China Early Toxicity Testing Market
Indonesia Early Toxicity Testing Market
Australia Early Toxicity Testing Market
Taiwan Early Toxicity Testing Market

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions.' AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

David Correa
Allied Analytics LLP
800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

MENAFN04082022003118003196ID1104647757


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.